![](\"https:\/\/mms.businesswire.com\/media\/20260611875114\/en\/2829965\/5\/Dr._Shah_REMEDY.jpg\")
<\/a><\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260611875114\/en\/2829958\/5\/REMEDY_Logo.jpg\"){kind=logo}
<\/a><\/a>\nFounded by board-certified dermatologist Dr. Muneeb Shah, REMEDY was created to mirror the way dermatologists approach skin in clinic: starting with the patient concern, meticulously formulating to create advanced solutions, and prioritizing visible results without compromising skin health. The brand\u2019s portfolio addresses the concerns dermatologists see every day, including dark spots, dryness, fine lines, dullness, keratosis pilaris, and sensitive skin.<\/p>
\n\u201cFor years, I saw patients who were doing everything right but still struggling to find products that delivered meaningful results without irritation or unnecessary complexity. REMEDY was created to modernize dermatologist-developed skincare,\u201d said Dr. Muneeb Shah, founder and CEO of REMEDY. \"Each formula starts with a real patient need. We then innovate with the latest ingredient technologies to create clinically tested, high-efficacy formulas with a focus on visible results and safety for sensitive skin.\u201d<\/p>
\nREMEDY has grown exponentially since launching in March 2024, driven by the quality of the brand\u2019s products and its growing resonance with consumers who are overwhelmed by the breadth of skincare solutions in the market today and drawn to REMEDY\u2019s effective solutions grounded in science. The brand has experienced significant growth across all online channels, its direct-to-consumer website, Amazon, and TikTok Shop. The business also has seen breakout success in Target following its December 2025 nationwide launch in the retailer.<\/p>
\n\"We seek to partner with exceptional founders building brands that will redefine categories, and we believe REMEDY is uniquely modernizing dermatological skincare,\" said Tehmina Haider, Partner at L<\/i> Catterton. \"As both a clinician and a consumer educator, Dr. Shah has built a portfolio of simple, effective, and accessibly priced products that leverage advanced ingredient technologies to address real patient needs \u2014 and that is what will define the next generation of dermocosmetics. The brand's rapid growth reflects deep consumer demand for affordable, clinically-grounded skincare, and we are thrilled to partner with the REMEDY team on their next chapter.\"<\/p>
\nNorwest, which led REMEDY\u2019s seed round, is also deepening its commitment to the company through participation in the Series A.<\/p>
\n\u201cSince our initial investment, REMEDY has scaled rapidly across all channels and built consumer trust by delivering what today\u2019s skincare consumers are looking for: efficacy, simplicity, and accessibility,\u201d said Lisa Wu, Partner at Norwest. \u201cREMEDY is leading a new wave of clinical skincare without the traditional prestige price. We are thrilled to double down on our partnership and continue supporting their mission to make dermatological expertise and treatments accessible to all.\u201d<\/p>
\nThe Series A investment will support REMEDY\u2019s next phase of growth, including advancing clinical research, expanding its pipeline of dermatologist-developed products, building a best-in-class team and improving inventory depth to meet increasing demand across DTC, Amazon, and Target. The company also plans to deepen its capabilities across formulation, testing, and consumer education as it continues building a scaled dermocosmetic platform.<\/p>
\nThe partnership with L<\/i> Catterton also brings significant beauty category experience to REMEDY as the brand continues to scale.<\/p>
\nAbout REMEDY<\/p>
\nREMEDY is a dermatologist-developed skincare brand founded by board-certified dermatologist Dr. Muneeb Shah, whose evidence-based education has earned the trust of more than 20 million people globally. Built on the belief that everyone deserves access to healthy skin, REMEDY creates advanced daily essentials and targeted treatments inspired by real patient needs and formulated to deliver visible results while remaining safe for sensitive skin.<\/p>
\nFor more information, visit remedyskin.com.<\/p>
\nAbout L<\/i> Catterton<\/p>
\nL<\/i> Catterton is the largest global consumer-focused investment firm, managing approximately $40 billion of equity capital across three multi-product platforms: private equity, credit, and real estate. The firm\u2019s funds have the ability to invest between $5 million and $5 billion, across the capital structure, in well-positioned consumer businesses. Leveraging deep category insight, operational excellence, and a broad network of strategic relationships, L<\/i> Catterton\u2019s team of more than 200 investment and operating professionals across 18 offices partners with management teams to drive differentiated value creation across its portfolio. Current and historical L <\/i>Catterton investments in the category include Merit Beauty, TULA, ODDITY, Kopari, Elemis, Nutrafol, Intercos, Ex Nihilo, and many others. Founded in 1989, the firm has made over 300 investments in some of the world\u2019s most iconic consumer brands. For more information about L<\/i> Catterton, please visit www.lcatterton.com<\/a>.<\/p> \nMedia Contact:<\/b> Minority investment will support clinical research, product innovation, team expansion, and continued growth across DTC, Amazon, and TargetLOS ANGELES–(BUSINESS WIRE)–Remedy Science (\u201cREMEDY\u201d), the dermatologist-developed, education-first skincare b…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-19992","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19992"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19992\/revisions"}],"predecessor-version":[{"id":19993,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/19992\/revisions\/19993"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}